Press Releases

To see only press releases which have been disclosed pursuant to legislation or other regulations, please select “Regulatory releases” below.

Initiator Pharma announces outcome of rights issue

Initiator Pharma A/S (“Initiator” or the “Company”) announces the outcome of the Company’s rights issue of up to 14,039,590 shares (the “Rights Issue”), for which the subscription period ended on 26 June 2025. In the Rights Issue, 6 133 159 shares, corresponding to around 43.7 percent of the Rights Issue were subscribed through subscription rights. Additionally, 277 458 shares, corresponding to around 2.0 percent of the Rights Issue were subscribed without subscription rights. 5 670 164 shares, corresponding to around 40,4 percent of the Rights Issue were subscribed through guarantee undertakings. The Rights Issue will provide the Company with proceeds of approximately SEK 48.3 million before deduction of costs related to the Rights Issue.

The board of directors of Initiator Pharma A/S resolves on a rights issue amounting to SEK 56m

The board of directors of Initiator Pharma A/S (“Initiator” or the “Company”) has today, based on the authorisation from the general meeting held on 24 May 2024, resolved on a new issue of shares with pre-emption rights for the Company’s existing shareholders amounting to approximately SEK 56.2 million before issue costs (the “Rights Issue”). The Company has received subscription commitments from existing shareholders, including Linc and MAC Clinical Research, as well as members of the board of directors and management, amounting to approximately SEK 15 million, corresponding to approximately 27 percent of the Rights Issue. The Company has furthermore entered into guarantee undertakings with existing shareholders and external investors which, in aggregate, amount to approximately SEK 33 million, corresponding to approximately 59 percent of the Rights Issue. Consequently, the Rights Issue is covered by subscription commitments and guarantee undertakings amounting to approximately SEK 48 million, corresponding to approximately 86 percent of the Rights Issue.

Initiator Pharma expands FSD program to target vulvodynia. Signs financing agreement with MAC Clinical Research worth up to GBP 2.5 million.

Initiator Pharma A/S, a clinical-stage biotech company, today announced the expansion of its program in Female Sexual Dysfunction (FSD) to include vulvodynia, a severe chronic pain condition affecting approximately 10% of women worldwide. A Phase 2a clinical proof-of-concept study is expected to start in H2 2025, evaluating pudafensine as a potential treatment for vulvodynia. Funding of the Phase 2a study is secured through a convertible credit agreement with MAC Clinical Research worth up to GBP 2.5 million. The agreement gives MAC Clinical Research the right to convert the credit into Initiator Pharma shares upon the full completion of the planned Phase 2a study at a 40% premium to the TERP in a separately announced rights issue.